Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need to elucidate its molecular mechanisms to improve treatment and prognosis. Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is aberrantly expressed in lung cancer and is closely associated with malignant progression. As a member of the m6A-modified RNA-binding proteins, IGF2BP3 recognizes and binds to m6A-modified RNAs, thereby regulating RNA stability and translation, ultimately influencing cell proliferation, tumorigenesis, and patient outcomes. This review aims to comprehensively explore the molecular mechanisms by which IGF2BP3 contributes to lung cancer development and progression, and to discuss its potential applications in diagnosis, prognostic assessment, and therapeutic strategies.
Wu et al. (Tue,) studied this question.